boostrix polio suspensija injekcijām pilnšļircē
glaxosmithkline biologicals s.a., belgium - difterijas, stingumkrampju, acelulāra garā klepus un poliomielīta (inaktivēta) vakcīna (adsorbēta) - suspensija injekcijām pilnšļircē
engerix b 10 mikrogrami/0,5 ml suspensija injekcijām
glaxosmithkline biologicals s.a., belgium - b hepatīta (rdns) vakcīna - suspensija injekcijām - 10 µg/0,5 ml
engerix b 20 mikrogrami/ml suspensija injekcijām pilnšļircēs
glaxosmithkline biologicals s.a., belgium - b hepatīta (rdns) vakcīna - suspensija injekcijām pilnšļircē - 20 µg/ml
engerix b 10 mikrogrami/0,5 ml suspensija injekcijām pilnšļircēs
glaxosmithkline biologicals s.a., belgium - b hepatīta (rdns) vakcīna - suspensija injekcijām pilnšļircē - 10 µg/0,5 ml
engerix b 20 mikrogrami/ml suspensija injekcijām
glaxosmithkline biologicals s.a., belgium - b hepatīta (rdns) vakcīna - suspensija injekcijām - 20 µg/ml
hulio
biosimilar collaborations ireland limited - adalimumab - hidradenitis suppurativa; psoriasis; uveitis; arthritis, rheumatoid; spondylitis, ankylosing; crohn disease; colitis, ulcerative; arthritis, psoriatic - immunosuppressants, audzēja nekrozes faktora alfa (tnf-α) inhibitorus
zeposia
bristol-myers squibb pharma eeig - ozanimod hidrohlorīds - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imūnsupresanti - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
stamaril pulveris un šķīdinātājs injekciju suspensijas pagatavošanai pilnšļircē
sanofi pasteur europe, france - dzeltenā drudžea vakcīna (dzīva) - pulveris un šķīdinātājs injekciju suspensijas pagatavošanai
cimzia
ucb pharma sa - certolizumaba pegols - krona slimība - imūnsupresanti - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia var tikt dota monotherapy gadījumā, ja nepanes metotreksātu vai, ja turpina terapiju ar metotreksātu ir nevietā. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.
engerix b 20 mikrogrami/1 ml suspensija injekcijām pilnšļircē
glaxosmithkline biologicals s.a., belgium - b hepatīta (rdns) vakcīna - suspensija injekcijām pilnšļircē - 20 µg/ml